The Native Antigen Company, contract service provider to the in vitro diagnostics industry based in Oxford, UK, has launched a new purified Bordetella pertussis toxin.

The toxin was developed in response to the increasing pressure on the in vitro diagnostics industry to supply highly specific, cost-effective antibody capture systems, which are needed to monitor vaccination programmes.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

It is available in lyophilised format for ease of storage and use.

Pertussis, the condition caused by this bacterium, is a major cause of childhood morbidity and mortality.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now